Tag Archives: sny

Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

Big pharmas Pfizer (PFE) and Merck (MRK) both beat Q2 estimates and raised guidance Tuesday, while Merck and French counterpart Sanofi (SNY) entered into separate deals to develop immunotherapy drugs for cancer. Pfizer’s earnings dipped 3% to 56 cents a share, but topped analysts’ consensus by 4 cents, according to Thomson Reuters. Sales declined 7% to $11.85 billion, more than $400 million ahead of the Street’s number. Pfizer now sees full-year

Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK

Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the stock market today, but that was little changed from when shares were halted at 542.01 for much of the afternoon. The FDA announced approval of Praluent for patients with a genetic predisposition to high

Alnylam Reports Data on Potential Alexion Rival Drug

Biotech Alnylam Pharmaceuticals (ALNY) reported positive data Friday on a rare-disease drug candidate and potential competitor to Alexion’s (ALXN) blockbuster Soliris. The market was underwhelmed, however, and Alnylam stock was down more than 3% in midday trading. Alnylam reported initial results from a phase 1/2 trial of ALN-CC5, a drug it’s developing with Sanofi’s (SNY) Genzyme division that targets complement component C5. Complements are